Key Takeaways
- • EQT has agreed to take QIAGEN private through a recommended, all-cash voluntary public takeover offer of €46.50 per share, valuing the company at approximately €10.8 billion in enterprise value (about $12.1 billion including roughly $1.1 billion of net debt), according to QIAGEN; Reuters put the equity value at about €9.6 billion.
- • The offer represents a 40.3% premium to QIAGEN's XETRA close of €33.15 on July 8, 2026, but only 8.6% above the most recent close, as much of the bid was priced in after months of takeover speculation.
- • The bidder, Crown NL Bidco B.V., is indirectly controlled by the EQT XI fund, with co-investment participations from a wholly owned subsidiary of the Abu Dhabi Investment Authority and CPP Investment Board Europe.
- • The transaction requires a 50% plus one share minimum acceptance threshold, an extraordinary general meeting resolution, and merger control and foreign investment clearances, with closing expected in mid-2027.
- • The deal follows Thermo Fisher Scientific's abandoned 2020 bid of about $11.5 billion, which failed to win sufficient shareholder support.
Summary
EQT has agreed to take QIAGEN private through a recommended, all-cash voluntary public takeover offer of €46.50 per share. QIAGEN said the transaction values the molecular testing company at approximately €10.8 billion in enterprise value, or about $12.1 billion including roughly $1.1 billion of net debt, while Reuters put the equity value at about €9.6 billion. The bidder, Crown NL Bidco B.V., is indirectly controlled by the EQT XI fund. Co-investment participations are held by a wholly owned subsidiary of the Abu Dhabi Investment Authority and by CPP Investment Board Europe, part of Canada Pension Plan Investment Board.
The offer represents a 40.3% premium to QIAGEN's XETRA close of €33.15 on July 8, 2026, the last trading day before reports of private equity takeover interest, and a 46.9% premium to the three-month volume-weighted average price up to that date. Measured against the most recent close, Reuters reported the premium was 8.6%, reflecting the extent to which the bid had already been priced in after months of speculation. QIAGEN's U.S.-listed shares rose 0.7% in extended trading following the announcement.
QIAGEN's supervisory and managing boards fully support the deal and unanimously recommend that shareholders accept. Completion is subject to a minimum acceptance threshold of 50% of outstanding share capital plus one share, resolutions at an extraordinary general meeting including approval of post-closing measures, and merger control and foreign investment clearances. EQT has secured equity and debt financing, and closing is expected in mid-2027. If required approvals remain pending ten months after the announcement, QIAGEN may pay shareholders an interim dividend of up to $0.47 per share without reducing the offer price. QIAGEN has suspended its full-year 2026 outlook pending the transaction; preliminary third-quarter net sales were $548 million and adjusted diluted earnings per share were $0.65.
The deal closes a long period of takeover attention for the Dutch company. Thermo Fisher Scientific agreed in 2020 to acquire QIAGEN in a transaction valued at about $11.5 billion but abandoned the bid after failing to secure enough shareholder support.
For allocators, the structure follows the familiar large-cap European template: a flagship buyout fund takes control while sovereign and pension co-investors share the equity check. The acceptance threshold is set at a simple majority rather than a higher squeeze-out level. The 50%-plus-one condition, combined with post-closing measures, gives the sponsor a path to full ownership even if a meaningful minority does not tender, a dynamic in which the gap between the 40.3% headline premium and the 8.6% premium to the last close may prove significant.
The offer represents a 40.3% premium to QIAGEN's XETRA close of €33.15 on July 8, 2026, the last trading day before reports of private equity takeover interest, and a 46.9% premium to the three-month volume-weighted average price up to that date. Measured against the most recent close, Reuters reported the premium was 8.6%, reflecting the extent to which the bid had already been priced in after months of speculation. QIAGEN's U.S.-listed shares rose 0.7% in extended trading following the announcement.
QIAGEN's supervisory and managing boards fully support the deal and unanimously recommend that shareholders accept. Completion is subject to a minimum acceptance threshold of 50% of outstanding share capital plus one share, resolutions at an extraordinary general meeting including approval of post-closing measures, and merger control and foreign investment clearances. EQT has secured equity and debt financing, and closing is expected in mid-2027. If required approvals remain pending ten months after the announcement, QIAGEN may pay shareholders an interim dividend of up to $0.47 per share without reducing the offer price. QIAGEN has suspended its full-year 2026 outlook pending the transaction; preliminary third-quarter net sales were $548 million and adjusted diluted earnings per share were $0.65.
The deal closes a long period of takeover attention for the Dutch company. Thermo Fisher Scientific agreed in 2020 to acquire QIAGEN in a transaction valued at about $11.5 billion but abandoned the bid after failing to secure enough shareholder support.
For allocators, the structure follows the familiar large-cap European template: a flagship buyout fund takes control while sovereign and pension co-investors share the equity check. The acceptance threshold is set at a simple majority rather than a higher squeeze-out level. The 50%-plus-one condition, combined with post-closing measures, gives the sponsor a path to full ownership even if a meaningful minority does not tender, a dynamic in which the gap between the 40.3% headline premium and the 8.6% premium to the last close may prove significant.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.